Recruiting

Observational Study

Sponsor:

Centers for Disease Control and Prevention

Code:

NCT01772602

Conditions

Amyotrophic Lateral Sclerosis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The purpose of this registry is to (A) better describe the incidence and prevalence of Amyotrophic Lateral Sclerosis (ALS) in the United States;(B) examine appropriate factors, such as environmental and occupational, that may be associated with the disease; (C) better outline key demographic factors (such as age, race or ethnicity, gender, and family history of individuals who are diagnosed with the disease) associated with the disease; and (D) better examine the connection between ALS and other motor neuron disorders that can be confused with ALS, misdiagnosed as ALS, and in some cases progress to ALS.

Conditions

Amyotrophic Lateral Sclerosis

Study ID

NCT01772602

Start date

Oct, 2010

Status verified date

Apr, 2026

Completion date

Dec, 2040

Anticipated

Primary completion date

Dec, 2040

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

\- U.S. citizens 18 years of age or older

Exclusion Criteria:

\-

Study Design

Enrollment

30000 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • The National Amyotrophic Lateral Sclerosis (ALS) Registry [ Time Frame: 1 year ]

Central Contacts and Locations

Central contacts

Kevin Horton, DrPH, MSPH

770-488-1555dhorton@cdc.gov

Locations

CDC

Recruiting

Atlanta, Georgia, United States, 30333

Contacts

Kevin Horton, DrPH, MSPH

770-488-1555dhorton@cdc.gov

Principal Investigator:

Paul Mehta, MD

More Information

Sponsor

Centers for Disease Control and Prevention

Last update posted

Apr 29, 2026

Last verified

Apr, 2026

Keywords

  • Amyotrophic Lateral Sclerosis
  • Lou Gehrig's Disease
  • Motor Neuron Disease

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Centers for Disease Control and Prevention on 2026-04-29.